Ovarian Cancer: Symptoms, Treatment & When to Seek Care

When clinicians say “ovarian cancer” on tumour boards they are usually bundling invasive epithelial cancers arising from the ovarian surface epithelium, related fallopian tube mucosa, or widespread peritoneal lining—histologies and IHC patterns differ (high-grade serous, endometrioid, clear cell, mucinous, low-grade serous), yet many front-line treatment algorithms resemble one another closely enough to discuss jointly; rare germ-cell and sex-cord stromal tumours follow different timelines and are not the default mental model on a gynecologic oncology ward.

High-grade serous carcinoma, the dominant histology, behaves aggressively, seeds the omentum and peritoneal reflections early, and classically arrives with vague abdominal symptoms rather than a well-defined pelvic mass, which is why CA-125, expert pelvic ultrasound morphology scoring, and low-threshold referral language appear in UK NICE and US triage literature alike.

Definitive diagnosis is histologic—obtained via surgery or image-guided biopsy when surgery is unsafe—supported by tumour markers and sometimes next-generation sequencing panels that later unlock PARP inhibitor maintenance when BRCA loss or HRD signatures emerge.

FIGO 2014 (with subsequent clarifications) assigns stage I–IV based on local ovarian/tube extension, nodal involvement, and carcinomatosis burden. Nurses documenting postoperative summaries should capture the phrase residual disease (RD) because chemotherapy response and prognosis correlate with whether cytoreduction left no macroscopic tumour (R0 ideal) versus centimetre-class residual nodules after debulking; larger residual nodules often drive earlier platinum resistance.

↔On a small screen, swipe or scroll sideways to see the full table.

Pair stage discussions with pathology grade, CA-125 kinetics during chemotherapy, and molecular results—not with nurse-led predictions about survival intervals.

Typical epithelial presentations

Persistent new-onset abdominal bloating, pelvic pressure, early satiety, urinary urgency without infection, and low-grade abdominal pain often trail malignancy by months—patients may normalise symptoms against menopause or weight change.

Atypical or subtle cues

Isolated fatigue, nausea, change in bowel habit, and unexplained weight loss deserve structured examination and directed imaging when risk factors or age suggest malignancy.

Populations easy to underestimate

Older nulliparous women, BRCA / Lynch carriers, patients with longstanding endometriosis-linked histologies, and anyone minimising pain (“I didn’t want to bother anyone”)—use interpreter services and document safeguarding concerns when cognition or social barriers obscure history.

• BRCA1 / BRCA2 pathogenic variants: elevate ovarian and related tubal/peritoneal risk—link families to breast cancer pedigrees when relevant.
• Lynch syndrome (MMR gene defects): drives endometrioid / mismatch-repair deficient tumours—colon and endometrial history matter.
• Reproductive/endocrine history: nulliparity, early menarche, late menopause modestly shift risk in epidemiologic models.
• Protective factors: multiparity, oral contraceptive exposure, tubal ligation/salpingectomy narratives—help contextualise but never dismiss new symptoms.
• Environmental: associations (talc, perineal dusting) remain debated—cite uncertainty rather than implying certainty.

Clinical assessment

Bimanual examination may reveal fixed pelvic masses or cul-de-sac nodularity but lacks sensitivity for small-volume carcinomatosis—never reassure because a speculum exam felt “normal.”

Laboratory investigations

CA-125 (MUC16) tracks many epithelial cancers yet misses early disease and elevates with ovarian cysts, pelvic inflammatory disease, endometriosis, fibroids, and pleural disease—trend alongside symptoms rather than chasing single points. Add complete blood count, renal/hepatic panels (electrolyte panel, liver function tests) ahead of chemotherapy; consider HE4 where regional pathways embed Risk of Ovarian Malignancy Algorithm (ROMA) style tools.

Imaging

Transvaginal ultrasound details adnexal morphology; abdominal CT or MRI aids upper abdominal / liver surface mapping when planning surgery; CT chest completes staging when extrapelvic disease is suspected.

Diagnostic criteria & pathways

UK primary care often uses CA-125 with explicit ultrasound triggers (see NICE NG12 ovarian cancer section); US evaluation emphasises specialist referral for persistent unexplained symptoms with imaging. FIGO staging itself is surgical–pathologic in operable presentations; biopsy-only staging in NACT pathways should still anchor documentation.

1. Primary care / ambulatory cue: persistent new abdominal-pelvic symptoms in at-risk demographics → CA-125 + urgent pelvic ultrasound → refer on suspected malignancy pathway.
2. Specialist confirmation: CT chest/abdomen/pelvis, tissue diagnosis (surgery vs CT-guided biopsy), MDT tumour board assignment—including genetics liaison when BRCA panels pending.
3. Operability assessment: fitness, nutrition, ascites control, and predicted cytoreduction → choose primary debulking vs neoadjuvant chemotherapy with planned interval surgery.
4. Chemotherapy initiation: vascular access planning (central line care bundles), antiemetic ladders (ondansetron, dexamethasone), allergy review, and laboratory review pre-cycle.
5. Response assessment: CA-125 kinetics + imaging (often CT) + clinician exam → document fit for maintenance PARP inhibitor trials or bevacizumab continuation per formulary.
6. Relapse: rising marker, new effusions, or interval imaging growth → salvage chemotherapy vs clinical trial vs supportive focus—mapped by gynecologic oncology, not ward improvisation.

• Benign functional cysts or endometriomas—correlate with menstrual history and ultrasound morphology.
• Pelvic inflammatory disease / tubo-ovarian abscess—fever, cervical motion tenderness, infection markers.
• Omental cake from colon cancer or other GI primaries—colonoscopy and tumour markers as indicated.
• Metastatic breast cancer—clinical history and receptor profiling differ.
• Tuberculosis peritonitis—epidemiologic risk; ADA or microbiology where endemic.

First-line cytoreduction + platinum backbone

Fit patients with resectable disease undergo primary debulking aiming for minimal residual disease; others receive neoadjuvant chemotherapy (commonly carboplatin AUC-calculated plus paclitaxel every-three-weeks or weekly dose-dense variants per protocol) followed by interval surgery when tumour biology shrinks sufficiently. Intraperitoneal or heated intraperitoneal chemotherapy appears in selected centres—follow trial enrollment or local standard operating procedures.

Anti-angiogenic and maintenance layers

Bevacizumab may continue in select first-line HRD-high or high-risk relapse settings per regulatory labels and funding rules. After partial or complete response, PARP inhibitors (olaparib, niraparib, rucaparib—availability varies) extend progression-free intervals when BRCA mutations or HRD tests satisfy formulary criteria; nurses verify tablet strength changes between trial and commercial supplies.

Recurrent platinum-sensitive disease

Re-challenge platinum doublets, weekly taxane strategies, or liposomal doxorubicin appear per gynecologic oncology choice; symptom control with morphine equivalents and antiemetics escalates in parallel rather than sequentially when pain dominates.

Special populations

Older frail adults merit dose attenuation discussions; renal impairment adjusts carboplatin AUC assignments; borderline tumours in younger patients may permit fertility-sparing trials—document contraception counseling when teratogenic oral agents appear in research pathways.

• Chemotherapy day coordination: Verify cycle day, CBC/platelet thresholds, neuropathy grade, and allergy bands in medication reconciliation before IV infusion pump setup.
• Vascular access device care: Prehydration orders, pump occlusion alarms, and blood-return policy for implanted ports mirror unit oncology standards.
• Medication administration checks: Paclitaxel often requires prolonged observation for hypersensitivity; carboplatin hypersensitivity late in therapy still occurs—keep emergency tray per policy.
• Symptom stewardship: Pain assessment scores, antiemetic timing around PARP tablets, and constipation prophylaxis while on 5-HT3 blockers.
• Ascites pathway: Record pre- and post-drain weights, albumin replacement orders, clotting concerns, and patient positioning for respiratory comfort.
• Follow-up testing: CA-125 cadence (often 3-monthly initially then 6-monthly if stable—confirm local protocol), CT scheduling reminders, inherited-cancer clinic appointments when germline testing pending.
• Escalation triggers: New fever with rigid abdomen, brown surgical wound discharge, calf swelling suggesting VTE, hematemesis, or CA-125 doubling faster than baseline kinetics suggest.

• Intestinal obstruction or fistula from carcinomatosis—high NG tube output, worsening colicky pain, acidosis.
• Malignant ascites causing renal compromise, diaphragmatic splinting, malnutrition.
• Chemotherapy toxicity: Sensory neuropathy, myelosuppression, mucositis, hypersensitivity.
• Anemia of chronic disease plus marrow suppression—consider iron deficiency anemia work-up if bleeding present.
• Thromboembolism—maintain mechanical prevention and pharmacist-led anticoagulation when prescribed.

Multicentre screening trials (transvaginal ultrasound ± CA-125) have not convincingly cut mortality at population level; emphasis remains symptom awareness and risk-stratified genetic pathways (USPSTF BRCA-related testing guidance; NICE NG241 familial risk). Opportunistic salpingectomy at benign hysterectomy is debated but increasingly discussed for average-risk patients—document informed consent conversations without nurse-led guarantees.

SEER’s overview cites roughly half of women alive at five years across all stages combined, yet FIGO stage dominates: localized disease retains far higher relative survival than stage III–IV high-grade serous cancers where recurrence after platinum-free intervals still guides “platinum sensitivity” language. Anchor discussions to tumour board notes, surgical residual class, molecular eligibility for PARP, and patient performance status rather than internet averages alone.

Narrative cues families voice

Patients describe “my clothes shrinking” or “I can’t finish a slice of toast”—translate those domestic metrics into measurable abdominal girth and meal percentages for handover.

Documentation leverage

Serial symptom diaries beat single-day recall; photograph wound dressings only per policy but narrate drainage colour/text in structured notes for tele-reviewed surgeons.

• Confusion plus abdominal distension—consider opioid burden, hyperammonaemia from hepatic metastases, or sepsis, not “just anxiety.”
• Shoulder tip pain after paracentesis—possible diaphragmatic irritation or bleed—notify team.
• Paracentesis output slows abruptly with fresh blood—clamp line and escalate.

Bedside monitoring checklist

• Strict fluid balance when ascites or diuretics overlap.
• Neuropathy scores before each taxane dose—functional grip strength matters.
• Nutrition consult flag when satiety limits <50% meals × 72 h.
• Psychosocial touchpoint after BRCA result disclosures—offer genetics follow-up numbers.
• Teach infection thermometry before each neutropenic nadir window.

While activating pathways: secure large-bore access if shock suspected, group-and-save when surgical intervention possible, provide oxygen titrated to saturations, and hand over imaging discs plus latest CA-125 verbally to receiving teams.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze vocabulary on the topic of gynecologic oncology shifts—ascites/paracentesis safety, malignant bowel obstruction cues, CA-125 triage language, platinum-taxane toxicity patrol, febrile neutropenia bundles, and PARP documentation touchpoints aligned with the Clinical Judgment Measurement Model.